Clinical Trial

Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)

Study acronym: AVENHIR
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 5, 2026 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
Open-label phase II, single arm, multicenter study with safety run-in to evaluate the efficacy and safety of Azacitidine combined with Venetoclax in patients with higher-risk chronic myelomonocytic leukemia
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2023-03-03; most recent amendment 2026-03-03.
Status change: Recruiting → Active, Not Recruiting 2025-12-01
Status change: Not Yet Recruiting → Recruiting 2023-10-13
Trial Details
NCT Number NCT05768711
Lead Sponsor Groupe Francophone des Myelodysplasies
Collaborators: AbbVie
Conditions Chronic Myeloid Leukemia
Enrollment 44 participants
Start Date 2023-10-04
Primary Completion 2026-05 (estimated)
Study Completion 2028-10 (estimated)
Updated on ClinicalTrials.gov 2026-03-05